Novavax is trading at $10.97, up +5.38%, with no clear company-specific announcement identified for the September 22, 2026 move.
- Latest listed company updates concern investor conferences and 2026–2027 Nuvaxovid approvals, not a new September 22 catalyst.
- Broader markets are mixed and do not provide a strong direct explanation.
- The move may reflect positioning or follow-through from prior gains, but this remains unconfirmed.